Insight

Loay Kassem/X

Jan 11, 2025, 06:35

Loay Kassem: Six studies that could change my breast cancer practice based on SABCS 2024

Loay Kassem, Assistant Professor of Clinical Oncology at Kasr AlAiny School of Medicine, Cairo University, shared a post on LinkedIn:

“Six studies that could change my breast cancer practice based on SABCS 2024.

PATINA trial:

Adding palbociclib to standard-of-care maintenance endocrine therapy and antiHER2, improved PFS by more than 15 months in metastatic
Triple-positive breast cancer over standard-of-care treatment alone.

EMBER-3 study:

The new oral SERD, Imlunestrant, with or without abemaciclib had superior PFS compared to standard second-line endocrine therapy in metastatic, hormone receptor-positive, HER2-negative breast cancer post progression on aromatase inhibitor +/- a CDK4/6 inhibitor.
Published in NEJM Group.

BIG 2-04 MRC/ SUPREMO study:

Patients with intermediate-risk breast cancer (pT3N0, T2 N1) had similar rates of 10-year overall survival whether or not they received post-mastectomy chest wall irradiation.

INSEMA study:

Women with early-stage (mostly cT1 N0), low-risk breast cancer (mostly >50 years, ER+/HER2-) can skip sentinel LN biopsy with DFS and OS rates at five years compared to those who had SLNB.
Published in NEJM Group

COMET study:

Some patients with low-risk DCIS can defer standard-of-care surgery and radiotherapy and go instead on active monitoring (mammogram every 6 months and a biopsy if progressive).
At 2 years, the incidence of invasive cancer was very low in both groups. Of note, hormonal therapy was allowed in both groups. Published in JAMA Oncology.

New analysis from TAILORx study:

Anthracycline-based chemo offered higher distant recurrence-free survival compared to non-anthracycline chemo in patients with early node-negative ER+/HER2- breast cancer with an Oncotype Diagnosis Recurrence Score of 31 or higher.
The difference was higher in pT2 N0.

What is your opinion?

Any more practice-changing studies?”

loay-kassem-breast-cancer